Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | KLK1 | P06870 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747980 | 0.98 | CYP1A2 (0.50) | CYP1A2CYP2A6IDO1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL6634923 | 0.97 | CYP1A2 (0.48) | CYP1A2CYP2A6IDO1HTR2AHTR2C | |
| Bromide SCHEMBL6168962 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2A6IDO1HTR2AHTR2C | |
| Bromide SCHEMBL20677866 | 0.83 | IDO1 (0.65) | IDO1SLC11A2NOS3NOS1NOS2 | |
| SCHEMBL13256324 | 0.81 | CYP1A2 (0.43) | CYP1A2CYP2A6IDO1HTR2AHTR2C | |
| SCHEMBL20677854 | 0.81 | SLC11A2 (0.65) | IDO1SLC11A2NOS3NOS1NOS2 | |
| SCHEMBL6399707 | 0.81 | CYP1A2 (0.50) | CYP1A2CYP2A6IDO1HTR2AHTR2C | |
| Bromide SCHEMBL15346737 | 0.80 | CYP1A2 (0.46) | CYP1A2CYP2A6IDO1HTR2AHTR2C | |
| Bromide SCHEMBL30377322 | 0.80 | CYP1A2 (0.46) | CYP1A2CYP2A6IDO1PLAUF2 | |
| Bromide SCHEMBL3367273 | 0.80 | CYP1A2 (0.46) | CYP1A2CYP2A6IDO1PLAUF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110818-B1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170267657-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2017-09-21 | — | — | US | disclosed |
| CN-107074861-A | 9H pyrimido [4,5-B ] indoles and related analogs as BET bromodomain inhibitors | 密执安大学评议会 | 2017-08-18 | — | — | CN | disclosed |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-07-27 | — | — | US | disclosed |
| US-9708288-B2 | Pesticidal compositions and processes related thereto | DOW AGROSCIENCES LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-9591857-B2 | Pesticidal compositions and processes related thereto | DOW AGROSCIENCES LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-9580430-B2 | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-02-28 | — | — | US | disclosed |
| EP-3110818-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | The Regents of The University of Michigan (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160159766-A9 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2016-06-09 | — | — | US | disclosed |
| WO-2002036588-A2 | REVERSED AMIDINES AND METHODS OF USING FOR TREATING, PREVENTING, OR INHIBITING LEISHMANIASIS | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020045581-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering PAR-1 and optionally PAR-2 antagonists | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION | 2002-04-18 | — | — | US | disclosed |
| US-6365617-B1 | N-4-FLUOROPHENYLMETHYL-N-((1-(2,6-DICHLOROPHENYL)METHYL-3-(1-P YRROLI-DINYLMETHYL)-1H-INDOL-6-YL)AMINOCARBONYL)-CLYCINYL-L-ARGININ-N -BENZYL-AMIDE | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-04-02 | — | — | US | disclosed |
| US-20020037860-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indazole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION | 2002-03-28 | — | — | US | disclosed |
| WO-2001000659-A1 | BENZIMIDAZOLONE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000657-A2 | NOVEL INDOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000656-A2 | NOVEL INDAZOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000576-A1 | INDOLE AND INDAZOLE UREA-PEPTOIDS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0799191-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019440-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037860-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indazole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists | F2RL1, F2R, F2RL3 | SIGMAR1 4310/4885CYP1A2 761/4885CYP2A6 2750/4885 |
| US-20160159766-A9 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | ACHE, DDT, PTMS | SIGMAR1 3118/4885CYP1A2 78/4885CYP2A6 368/4885 |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | SIGMAR1 2695/4885CYP1A2 1598/4885CYP2A6 1326/4885 |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | SIGMAR1 2695/4885CYP1A2 1598/4885CYP2A6 1326/4885 |
| US-20020045581-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering PAR-1 and optionally PAR-2 antagonists | F2RL1, F2R, F2RL3 | SIGMAR1 4414/4885CYP1A2 1697/4885CYP2A6 2772/4885 |
| US-20170267657-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | ACHE, DDT, PTMS | SIGMAR1 3118/4885CYP1A2 78/4885CYP2A6 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.